BJMO - volume 19, issue 2, march 2025
S. Gutfreund MD, A. Vandebroek MD, S. Mignon MD, A. De Vocht MD, D. Schrijvers MD, PhD
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are frequently used in combination with endocrine therapy for the treatment of hormone receptor positive breast cancers. This paper reports two cases of patients with digoxin intoxications due to CDK4/6 inhibitors, one involving ribociclib and the other abemaciclib. Digoxin intoxication can lead to fatal arrhythmias, highlighting the need for further research to analyse and clarify the underlying pathophysiology. It is advisable to monitor drugs with a narrow therapeutic index when prescribing CDK4/6 inhibitors. Importantly, common medication interaction checkers such as Uptodate, Medscape and WebMD do not report interactions between CDK4/6 inhibitors and digoxin.
(BELG J MED ONCOL 2025;19(2): 73–77)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
